(2) Press release of September 30, 1999 entitled "Bristol-Myers Squibb Files New Drug Application for Novel Oral Antidiabetic Drug".

As seen from the enclosed Declaration, the inventor has established reduction to practice prior to July 15, 1998. Accordingly, it will be apparent that the inventor has established reduction of practice of her invention prior to the effective date as a reference of each of Erle et al. (1999) and Press Release (September 30, 1999), thereby removing Erle et al. and Press Release as references against the subject application.

With the filing of the executed Declaration under Rule 131, it is believed that Claims 37, 45 to 54, 58 to 60 and 71 to 73 and 75 to 79 are in condition for allowance.

Enclosed is the Erle et al. reference as requested.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: Feb. 3, 2003

Reg. No. 22,076

Attorney for Applicant

Burton Rodney